Study of PTC844 for active rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests an investigational medicine called PTC844 in people with active rheumatoid arthritis (RA) to see if it can reduce joint inflammation and symptoms. It may be an option if you've just been diagnosed or if your current treatment isn't working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rheumatoid arthritis confirmed by a doctor's diagnosis.
- Your RA is active, meaning you have moderate or high disease activity (a score of 3.2 or higher on a standard test).
- You have not yet been treated with disease-modifying drugs for RA, or you haven't responded well to or couldn't tolerate them.
- If you're on allowed background medications (like methotrexate, hydroxychloroquine, sulfasalazine, or low-dose prednisone), they need to be at a stable dose for at least 30 days before the study and stay that way.
- You must have a blood test showing inflammation (CRP level of at least 5 mg/L).
- You cannot have certain other conditions like blood disorders, past cancer (unless minor skin cancer), or other joint diseases (like fibromyalgia).
- Your RA must have started at age 18 or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
This trial tests a new medicine called CIT-013 for people with rheumatoid arthritis. It aims to see if CIT-013 can help reduce joint swelling and pain when added to your current treatment.
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.